TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Silexion Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Silexion Therapeutics Corp
Silexion Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

Silexion Therapeutics reported strong preclinical results for SIL204, a potential cancer therapy targeting KRAS mutations, raised $9.5 million in financing, and remains on track to initiate Phase 2/3 clinical trials in the first half of 2026.

Insights
HKHHY   positive

Successfully raised €1.3 billion in Notes with competitive interest rates, indicating strong financial positioning and market confidence


SLXN   positive

Demonstrated positive preclinical data across multiple cancer types, successfully raised capital, regained Nasdaq listing compliance, and maintained clear progress toward clinical trial initiation